• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

QT Vascular expands pivotal trial of Chocolate Touch DCB

January 16, 2019 By Sarah Faulkner

QT Vascular updated logoQT Vascular said today that the FDA approved the company’s request to expand an on-going pivotal study of its Chocolate Touch drug-coated balloon to include the use of atherectomy for lesion preparation.

The U.S. regulatory agency also approved the addition of subgroup analysis related to the use of atherectomy.

The pivotal study of QT Vascular’s drug-coated balloon includes patients with disease in the superficial femoral and popliteal arteries in the legs.

Study participants are randomized 1:1 to receive either the Chocolate Touch device or C. R. Bard (NYSE:BCR) Lutonix drug-coated balloon, according to QT Vascular. The study’s endpoints include procedural successes, freedom from bail-out stenting, patency and target lesion revascularization.

“The inclusion of atherectomy in the study is a unique element that expands the potential use of Chocolate Touch, both in hospitals and OBL,” principal investigator Dr. Mehdi Shishehbor said in prepared remarks. “The study will provide an important data set that is consistent with real world practice, especially at OBL where more and more patients are getting treated.”

QT Vascular launched its U.S. pivotal trial for Chocolate Touch in July 2017.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: C.R. Bard, QT Vascular

IN CASE YOU MISSED IT

  • Tandem Diabetes Care delivers 1 million insulin boluses using t:connect mobile app
  • Nuvo, Sheba Medical Center develop AI-powered gestational diabetes management platform
  • Verily’s Onduo, Sword Health collaborate on virtual diabetes care
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS